MedLife launches the EarlyCDT® test, which allows early detection of lung cancer by identifying specific autoantibodies, available in all its units.
Delia Niculescu
Current Affairs
foto:shutterstock
Always see our news on Google
MedLife Group, the leading private healthcare provider in Romania, has introduced the EarlyCDT® test, a blood-based immunologic test for the early detection of lung cancer. It identifies autoantibodies produced by the body up to 4 years before visible lesions appear. The test is non-invasive and is mainly targeted at people with risk factors, with a turnaround time of about 15 days. Studies show that the use of this test reduces late-stage diagnoses by 36%, increasing the chances of survival. MedLife reaffirms its commitment to innovation in laboratory medicine.
Sources
MedLife introduce în premieră în România testul EarlyCDT®, un test de sânge pentru depistarea timpurie a cancerului pulmonar
Inovație în medicina de laborator: MedLife introduce în premieră în România testul EarlyCDT®, un test de sânge pentru depistarea timpurie a cancerului pulmonar
MedLife introduce în premieră în România testul EarlyCDT®, un test de sânge pentru depistarea timpurie a cancerului pulmonar
Latest News
22:50
The Danube is approaching a new historic minimum. Romanian Waters warns: the next two weeks are critical.
22:10
Devastating explosion in a cafe in Moscow: three dead and 15 injured
21:32
Sorin Grindeanu sent a message of support for Spain in the context of the migration challenges in Ceuta: "it was there when it mattered"
21:04
The circulation of trucks will be prohibited on Sunday in the counties of Arad, Bihor, and Satu Mare, due to the heatwave.
20:36
WHO Alert: The Ebola epidemic in the Democratic Republic of the Congo is rapidly intensifying, becoming the largest in the country's history.
See more news
NEWS ON THE SAME TOPICS
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
